Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing alzheimers gaps, sorted by Newest.
Development and clinical validation of blood-based biomarkers for early Alzheimer's detection
alzheimers proposed 71%Current diagnostic methods rely heavily on invasive CSF collection or expensive imaging. There is a critical need for validated blood-based biomarkers that enable detection of preclinical or early-stage Alzheimer's disea…
gap-landscape-1388f2483ad1Mechanistic understanding of neuroinflammatory pathways in Alzheimer's disease progression
alzheimers proposed 70%While inflammatory processes are recognized as central to Alzheimer's pathogenesis, the specific molecular mechanisms linking neuroinflammation to tau pathology, amyloid aggregation, and neuronal loss remain incompletely…
gap-landscape-620d0836b334Scalable technology-enabled dementia care models for rural populations
alzheimers proposed 65%The existence of a dedicated rural dementia caregiver project indicates significant geographic disparities in dementia care access. Research into scalable telehealth, remote monitoring, and caregiver support technologies…
gap-landscape-64d8c5ef4a00Mechanistic basis of traumatic brain injury as an Alzheimer's risk factor
alzheimers proposed 67%The supportive care model for dementia and TBI comorbidity suggests an underexplored link between TBI and AD risk. The specific biological mechanisms through which traumatic brain injury accelerates or triggers Alzheimer…
gap-landscape-7318c960cfecOptimal integration of immunomodulatory therapies with existing Alzheimer's treatments
alzheimers proposed 64%The ongoing GM-CSF trial represents a novel immunomodulatory approach, but optimal sequencing, combination, or stratification of such immune-based therapies with cholinesterase inhibitors or anti-amyloid antibodies remai…
gap-landscape-26d6b4b75fceIntegrated mechanistic studies of traumatic brain injury as an AD risk factor
alzheimers proposed 67%A trial addressing TBI-dementia co-morbidity exists, but the representative papers lack mechanistic integration of repetitive TBI as a distinct pathomechanistic driver of AD pathology. Whether TBI accelerates amyloid agg…
gap-landscape-1bb20bf39fb5Culturally-adapted and diversity-inclusive dementia care intervention models
alzheimers proposed 64%The completed Rural Dementia Caregiver Project addresses one demographic context, but there is no evidence of interventions tailored for culturally diverse populations, urban underserved communities, or minority populati…
gap-landscape-5ebea5e21efaPrecision prevention trials targeting APOE4 homozygous carriers before symptom onset
alzheimers proposed 70%The crowding score (0.919) indicates saturation in general AD research, yet no trials address APOE4 homozygosity-specific prevention strategies despite this genotype conferring the highest lifetime risk. Gene-environment…
gap-landscape-5184cb62130eDisease-modifying therapies targeting tau pathology beyond anti-amyloid approaches
alzheimers proposed 65%The literature is heavily weighted toward amyloid-centric mechanisms and anti-inflammatory approaches (as evidenced by the GM-CSF trial), but specific therapeutic strategies targeting tau hyperphosphorylation, oligomeriz…
gap-landscape-ea6ca3416b71Validated blood-based biomarkers for Alzheimer's disease screening in primary care settings
alzheimers proposed 68%While inflammatory processes and diagnostic criteria are well-reviewed, there is a critical absence of validated, accessible blood-based biomarkers for early AD detection in community or primary care contexts. Current pa…
gap-landscape-59c85ee62ac4What mechanistic questions remain unresolved beyond current work on Alzheimer's disease.?
alzheimers proposed 52%Heuristic fallback gap synthesized from representative landscape paper: Alzheimer's disease.
gap-landscape-ad8437f20c58What mechanistic questions remain unresolved beyond current work on Pathogenesis of Alzheimer's Disease.?
alzheimers proposed 52%Heuristic fallback gap synthesized from representative landscape paper: Pathogenesis of Alzheimer's Disease.
gap-landscape-27624c87f3fcWhat mechanistic questions remain unresolved beyond current work on Current understanding of Alzheimer's disease diagnosis and treatment.?
alzheimers proposed 52%Heuristic fallback gap synthesized from representative landscape paper: Current understanding of Alzheimer's disease diagnosis and treatment.
gap-landscape-8e39587a258dWhy does the translational pipeline from AD animal models to human trials have such high attrition, and how can preclinical-to-clinical translation be improved?
alzheimers proposed 68%Despite high crowding (0.919), only one Phase II trial is currently recruiting. This suggests fundamental issues in translating mechanistic targets from rodent models to human biology remain an unsolved problem.
gap-landscape-79b248018628What combination strategies targeting multiple AD pathogenic pathways (Aβ, tau, inflammation, metabolism) demonstrate disease-modifying efficacy in humans?
alzheimers proposed 67%No current trials investigate combinatorial approaches. Single-target therapies have failed repeatedly, yet the field lacks systematic investigation of synergistic multi-target interventions.
gap-landscape-ebda7066ea30How can precision medicine approaches stratify AD patients into mechanistically distinct subtypes for targeted therapy selection?
alzheimers proposed 65%Current trial designs treat AD as monolithic despite evidence of heterogeneity. There are no ongoing studies attempting to match patients to therapies based on underlying pathogenic dominance patterns.
gap-landscape-b958495206d8What are the precise inflammatory signaling cascades linking microglial activation to neuronal loss in AD, and can specific nodes be targeted without immunosuppression?
alzheimers proposed 70%While inflammation is recognized as a pathomechanism, the specific molecular mechanisms by which chronic neuroinflammation drives tau aggregation and synaptic loss remain undefined. Current anti-inflammatory approaches h…
gap-landscape-3eb57ae7ecadHow can blood-based biomarkers be validated and implemented for widespread pre-symptomatic AD detection in clinical practice?
alzheimers proposed 67%Diagnosis papers from 2018 highlight limitations in early detection, and while p-tau217 assays show promise, there are no established protocols for integrating blood-based biomarkers into primary care screening for precl…
gap-landscape-345cacf1850dWhat molecular mechanisms mediate the bidirectional risk between traumatic brain injury and subsequent AD neurodegeneration?
alzheimers proposed 64%TBI is identified as a risk factor in supportive care models, yet mechanistically unresolved how acute brain trauma initiates chronic tau pathology years later. Only one trial is actively investigating this intersection.
gap-landscape-4c382d500a1dFluid biomarker-guided monitoring in immunomodulatory Alzheimer's trials
alzheimers proposed 64%Peripheral immune stimulation trials lack validated companion biomarkers for real-time CNS target engagement. Need for longitudinal CSF/plasma inflammation endpoints that correlate with clinical outcomes in immunotherapy…
gap-landscape-927fa8fffa13Combination therapy design: optimal sequencing of disease-modifying and supportive interventions
alzheimers proposed 60%Current trials evaluate single modalities. With immunotherapy now in Phase II, there is no framework for combining disease-modifying approaches with supportive care in a rational, biomarker-guided sequence.
gap-landscape-45059b28bff4Integration of non-pharmacological dementia care models into rural healthcare systems
alzheimers proposed 62%The completed Rural Dementia Caregiver Project generated findings but no published framework for scaling effective interventions to underserved populations. Implementation science gap: how to operationalize caregiver sup…
gap-landscape-e7d1d4cee323Inflammatory endotypes and biomarker-guided patient stratification for anti-inflammatory therapies
alzheimers proposed 67%While inflammation is recognized as central to AD pathogenesis, no validated inflammatory endotypes exist to guide personalized anti-inflammatory treatment selection. Blood or CSF biomarkers enabling stratification are a…
gap-landscape-5052d2923a62Precision medicine subtypes beyond amyloid/tau for targeted therapeutic development
alzheimers proposed 67%Despite high crowding (0.919), most trials target amyloid or generic inflammation. Identification of molecular endophenotypes (e.g., specific inflammatory subtypes, metabolic phenotypes) enabling stratified enrollment is…
gap-landscape-793f4828c9ce